Imunon (IMNN) Stock Price, News & Analysis

Company Overview

Imunon, Inc. (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies for the treatment of cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes or immune-stimulating agents directly to targeted tissues, with the goal of activating the body’s immune response against disease.

Its leading product candidate is IMNN-001, formerly known as GEN-1, an investigational DNA-based interleukin-12 immunotherapy being developed for advanced ovarian cancer. The candidate uses Imunon’s TheraPlas delivery platform, which combines plasmid DNA with a synthetic lipid-based delivery system and is intended to provide localized, sustained expression of the therapeutic protein.

Imunon was formerly known as Celsion Corporation and adopted its current name in 2022 to reflect its focus on immunotherapy and nucleic-acid delivery technologies. The company is headquartered in Lawrenceville, New Jersey, and conducts its development activities through clinical research and collaborations supporting its oncology pipeline.

Key Stats

• Today's Range: $1.34 to $1.45
• 50-Day Range: $1.35 to $1.77
• 52-Week Range: $1.30 to $5.55
• Volume: 91,203 shs
• Average Volume: 138,266 shs
• Market Capitalization: $7.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Imunon Stock Analysis - MarketRank™

Imunon scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Imunon has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Imunon has a consensus price target of $10.00, representing about 609.2% upside from its current price of $1.41.

Amount of Analyst Coverage

Imunon has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Imunon are expected to grow in the coming year, from ($2.37) to ($2.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Imunon is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Imunon is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Imunon has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.55% of the float of Imunon has been sold short.

Short Interest Ratio / Days to Cover

Imunon has a short interest ratio ("days to cover") of 1.26, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Imunon has recently increased by 114.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Imunon does not currently pay a dividend.

Dividend Growth

Imunon does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Imunon has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Imunon this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for IMNN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

5 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Imunon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,188.00 in company stock.

Percentage Held by Insiders

2.83% of the stock of Imunon is held by insiders.

Percentage Held by Institutions

4.47% of the stock of Imunon is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMNN
• CIK: 749647
• Web: www.imunon.com
• Phone: (609) 896-9100
• Fax: 609-896-2200
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Imunon: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +609.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -358.01%
• Return on Assets: -132.91%

Debt

• Debt-to-Equity Ratio: 2.86
• Current Ratio: 1.82
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.30 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 5,611,000
• Free Float: 5,452,000
• Market Cap: $7.91 million
• Optionable: Not Optionable
• Beta: 1.98